Page last updated: 2024-12-06

11-beta-chloromethyl-estradiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

11-beta-chloromethyl-estradiol (11β-CME) is a synthetic analog of estradiol, a naturally occurring female sex hormone. It's important in research because it possesses a unique combination of properties that makes it a valuable tool for studying estrogen receptors (ERs) and their role in various biological processes.

Here's why 11β-CME is significant for research:

**1. Selective ERα Agonist:** 11β-CME acts as a selective agonist for estrogen receptor alpha (ERα), meaning it preferentially binds to and activates ERα while having minimal or no activity on estrogen receptor beta (ERβ). This selectivity allows researchers to study the specific effects mediated by ERα, excluding the influence of ERβ.

**2. Non-steroidal Structure:** Unlike estradiol, 11β-CME is not a steroid molecule. This non-steroidal structure grants it some advantages:

* **Increased Stability:** It is more stable than estradiol, potentially extending its half-life and allowing for longer-lasting effects.
* **Improved Permeability:** It can potentially cross cell membranes more readily, making it more accessible to target tissues.

**3. Potential Applications in Research:**

* **ERα-mediated Signaling Pathways:** Understanding how 11β-CME interacts with and activates ERα provides insight into the downstream signaling pathways involved in various biological processes, including:
* **Cellular proliferation:** Estrogen is known to influence cell growth and division.
* **Bone metabolism:** Estrogen plays a crucial role in bone health and density.
* **Cardiovascular function:** Estrogen can impact blood vessel function and cardiovascular health.
* **Neurological processes:** Estrogen has been linked to mood regulation, cognition, and neuroprotection.
* **Development of ERα-targeted Therapies:** By understanding the specific actions of 11β-CME, researchers might be able to develop new drugs that target ERα for treating various diseases. This could include conditions related to estrogen deficiency, like osteoporosis, or conditions where ERα is implicated in disease progression, like certain cancers.

**However, it's important to note that 11β-CME is a research tool, not a therapeutic agent.** Its safety and efficacy in humans haven't been established.

In summary, 11β-CME is a valuable tool for research due to its selectivity for ERα, its non-steroidal structure, and its potential applications in investigating ERα-mediated signaling pathways and developing novel therapies.

Cross-References

ID SourceID
PubMed CID67088
CHEMBL ID175602
CHEBI ID34142
SCHEMBL ID8746070
MeSH IDM0116929

Synonyms (19)

Synonym
11beta-chloromethylestradiol
org 4333
71794-60-0
(8s,9r,11s,13s,14s,17s)-11-(chloromethyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
CHEMBL175602
chebi:34142 ,
unii-brp4dw4see
brp4dw4see ,
estra-1,3,5(10)-triene-3,17-diol, 11-(chloromethyl)-, (11beta,17beta)-
org-4333
11-beta-chloromethyl-estradiol
SCHEMBL8746070
11beta-chloromethylestra-1,3,5(10)-trien-3,17beta-diol
DTXSID40992450
Q27115844
estra-1,3,5(10)-triene-3,17-diol, 11-(chloromethyl)-, (11.beta.,17.beta.)-
11.beta.-cme2
11.beta.-chloromethylestradiol
(11.beta.,17.beta.)-11-(chloromethyl)estra-1,3,5(10)-triene-3,17-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID69391Binding affinity against estrogen receptor was determined by using [3H]estradiol as radioligand in competitive radiometric binding assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Ligands for the estrogen receptor, containing cyclopentadienyltricarbonylrhenium units.
AID69390Binding affinity against estrogen receptor was determined by using [3H]estradiol as radioligand in competitive radiometric binding assay1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Ligands for the estrogen receptor, containing cyclopentadienyltricarbonylrhenium units.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.12 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]